{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-001625","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2025-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.643142+00:00","generated_at":"2026-05-16T15:10:25.448006+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lunai Bioworks enters ATM sales agreement for up to $11.7M common stock offering","bullets":["Agreement with Dawson James Securities for at-the-market offering of up to $11.7M in common stock.","Sales Agent receives 3.0% commission on gross proceeds; reimbursed for certain expenses.","Shares sold under effective S-3 registration statement (File No. 333-282898).","Company not obligated to sell any shares; may suspend or terminate at any time with 10 days' notice.","Net proceeds intended for general corporate purposes (per prospectus supplement)."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-001625","json":"https://secwatch.observer/filing/0001731122-25-001625.json","markdown":"https://secwatch.observer/filing/0001731122-25-001625.md","text":"https://secwatch.observer/filing/0001731122-25-001625.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001625/0001731122-25-001625-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001625/e7056_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:10:25.448006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"995c365d707f5affda2108ae72c27dd22b039c22","claim":"Lunai Bioworks Inc. entered into At-the-Market Sales Agreement with Dawson James Securities, Inc. valued at up to $11.70 million (effective 2025-12-02).","evidence_excerpt":"On December 2, 2025, Lunai Bioworks, Inc. (the “Company”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell (the “Offering”) shares of its common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $11.70 million, from time to time through the Sales Agent as the Company’s sales agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225001625/0001731122-25-001625-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Dawson James Securities, Inc."},{"label":"Value","value":"up to $11.70 million"},{"label":"Effective","value":"2025-12-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}